83 related articles for article (PubMed ID: 20575660)
1. Toll-like receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in response to a plain polysaccharidic vaccine.
Taillardet M; Haffar G; Mondière P; Asensio MJ; Pléau-Pison T; Burdin N; Defrance T; Genestier L
J Infect Dis; 2010 Aug; 202(3):470-9. PubMed ID: 20575660
[TBL] [Abstract][Full Text] [Related]
2. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice.
Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
Scand J Immunol; 2009 Mar; 69(3):194-202. PubMed ID: 19281531
[TBL] [Abstract][Full Text] [Related]
3. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
Inoue J; Aramaki Y
Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
[TBL] [Abstract][Full Text] [Related]
5. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
[TBL] [Abstract][Full Text] [Related]
6. Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels.
Sen G; Chen Q; Snapper CM
Infect Immun; 2006 Apr; 74(4):2177-86. PubMed ID: 16552048
[TBL] [Abstract][Full Text] [Related]
7. The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells.
Taillardet M; Haffar G; Mondière P; Asensio MJ; Gheit H; Burdin N; Defrance T; Genestier L
Blood; 2009 Nov; 114(20):4432-40. PubMed ID: 19767510
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
Ma R; Du JL; Huang J; Wu CY
Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
[TBL] [Abstract][Full Text] [Related]
9. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
11. The effect of T cell independent and cross-reactive antigen on the immune response to pneumococcal conjugate vaccination.
Rabquer B; Smithson SL; Shriner A; Julie Westerink MA
Immunol Lett; 2006 Aug; 106(2):187-90. PubMed ID: 16781780
[TBL] [Abstract][Full Text] [Related]
12. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
[TBL] [Abstract][Full Text] [Related]
13. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration.
von Beust BR; Johansen P; Smith KA; Bot A; Storni T; Kündig TM
Eur J Immunol; 2005 Jun; 35(6):1869-76. PubMed ID: 15909311
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides stimulate cord blood mononuclear cells to produce immunoglobulins.
Landers CD; Bondada S
Clin Immunol; 2005 Sep; 116(3):236-45. PubMed ID: 15967728
[TBL] [Abstract][Full Text] [Related]
15. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo.
Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F
Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.
Oma K; Zhao J; Ezoe H; Akeda Y; Koyama S; Ishii KJ; Kataoka K; Oishi K
Vaccine; 2009 May; 27(24):3181-8. PubMed ID: 19446189
[TBL] [Abstract][Full Text] [Related]
18. Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae.
Smith CM; Lo Passo C; Scuderi A; Kolberg J; Baxendale H; Goldblatt D; Oggioni MR; Felici F; Andrew PW
Eur J Immunol; 2009 Jun; 39(6):1527-35. PubMed ID: 19499518
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand.
Salucci V; Mennuni C; Calvaruso F; Cerino R; Neuner P; Ciliberto G; La Monica N; Scarselli E
Scand J Immunol; 2006 Jan; 63(1):35-41. PubMed ID: 16398699
[TBL] [Abstract][Full Text] [Related]
20. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
